Synergy protects “financial health” without the sacrifice of extra pressure on share price, says Canaccord.
Hedge Fund Guru Mark Kingdon Isn’t Taking Any Risks with OTIC, SGYP, ATRS
Synergy Still Showcases Promising Commercial Trajectory in CIC Rodman & Renshaw analyst Ram Selvaraju still looks for momentum in Synergy Pharmaceuticals Inc’s (NASDAQ:SGYP) chronic idiopathic …
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) stock is on the downward spiral today, to the harsh, discordant clang of 12% after the biotech firm released …
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) reported its financial results and business update for the three months ended June 30, 2017. Synergy will host a …
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) shares were on a 4% cave yesterday on the heels of Express Scripts setting loose its 2018 National Preferred …
Express Scripts, a company that controls about 40 percent of the pharmacy benefit market, will exclude an additional 64 drugs from its national …
BTIG analyst Tim Chiang is optimistic in regard to continued long-term growth at Synergy Pharmaceuticals Inc (NASDAQ:SGYP). The company is taking a number of …
Oppenheimer analyst Derek Archila sees some short-term capital rocky waters for Synergy Pharmaceuticals Inc (NASDAQ:SGYP) and awaits more details post-Trulance launch, but continues to …
Second quarter earnings for the year are due sometime around mid-August from Synergy Pharmaceuticals Inc (NASDAQ:SGYP). Yet, for Canaccord analyst John Newman, consensus …
